| Health outcomes |
| Total non-severe cases <5 yrs averted |
468,167 |
| Total severe cases <5 yrs averted |
101,112 |
| Total outpatient visits averted |
301,148 |
| Total hospitalizations averted |
80,889 |
| Total deaths <5 yrs averted |
102 |
| DALYs (discounted) averted |
3,921 |
| Health system treatment costs |
| Outpatient visit costs averted |
$1,983,909 |
| Hospitalization costs averted |
$12,141,801 |
| Total health system treatment costs averted
|
$14,125,710
|
| Societal treatment costs |
| Outpatient visit costs averted |
$5,572,106 |
| Hospitalization costs averted |
$16,585,763 |
| Total societal treatment costs averted
|
$22,157,869
|
| Vaccine program costs |
| With ROTARIX (at $4 per dose) |
$19,044,961 |
| With ROTAVAC (at $1 per dose) |
$15,510,482 |
| With ROTAVAC (at $0.85 per dose) |
$14,826,329 |
| With ROTAVAC (at $1.5 per dose) |
$17,790,994 |
|
Cost per DALY averted (ROTAVAC at $1 per dose) |
| ROTARIX compared to no vaccine (health system perspective) |
$1,254 |
| ROTARIX compared to no vaccine (societal perspective) |
Cost-saving (-$794) |
| ROTAVAC compared to no vaccine (health system perspective) |
$353 |
| ROTAVAC compared to no vaccine (societal perspective) |
Cost-saving (-$1,695) |
| ROTAVAC compared to ROTARIX (health system perspective) |
Cost-saving (-$901) |
| ROTAVAC compared to ROTARIX (societal perspective) |
Cost-saving (-$901) |
